Guasch-Ferré, MartaRuiz-Canela, MiguelLi, JunZheng, YanBulló, MònicaWang, Dong DToledo, EstefaníaClish, ClaryCorella, DoloresEstruch, RamonRos, EmilioFitó, MontserratArós, FernandoFiol, MiquelLapetra, JoséSerra-Majem, LluísLiang, LimingPapandreou, ChristopherDennis, CourtneyMartínez-González, Miguel AHu, Frank BSalas-Salvadó, Jordi2023-01-252023-01-252019http://hdl.handle.net/10668/13180The potential associations between acylcarnitine profiles and incidence of type 2 diabetes (T2D) and whether acylcarnitines can be used to improve diabetes prediction remain unclear. To evaluate the associations between baseline and 1-year changes in acylcarnitines and their diabetes predictive ability beyond traditional risk factors. We designed a case-cohort study within the PREDIMED Study including all incident cases of T2D (n = 251) and 694 randomly selected participants at baseline (follow-up, 3.8 years). Plasma acylcarnitines were measured using a targeted approach by liquid chromatography-tandem mass spectrometry. We tested the associations between baseline and 1-year changes in individual acylcarnitines and T2D risk using weighted Cox regression models. We used elastic net regressions to select acylcarnitines for T2D prediction and compute a weighted score using a cross-validation approach. An acylcarnitine profile, especially including short- and long-chain acylcarnitines, was significantly associated with a higher risk of T2D independent of traditional risk factors. The relative risks of T2D per SD increment of the predictive model scores were 4.03 (95% CI, 3.00 to 5.42; P An acylcarnitine profile, mainly including short- and long-chain acylcarnitines, was significantly associated with higher T2D risk in participants at high cardiovascular risk. The inclusion of acylcarnitines into the model did not significantly improve the T2D prediction C-statistics beyond traditional risk factors, including fasting glucose.enAgedAged, 80 and overBiomarkersCardiovascular DiseasesCarnitineCase-Control StudiesDiabetes Mellitus, Type 2Diet, MediterraneanFemaleFollow-Up StudiesHumansIncidenceMaleMetabolomicsMiddle AgedPrognosisProspective StudiesROC CurveRisk Factorsresearch article30423132open access10.1210/jc.2018-010001945-7197PMC6435097https://academic.oup.com/jcem/article-pdf/104/5/1508/28224388/jc.2018-01000.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435097/pdf